Pet in lung cancer

Journal of Nuclear Medicine

Volumn 40, Issue 5, 1999, Pages 814-820

  Coleman, R Edward ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cancer; Diagnosis; Fluorodeoxyglucose; PET; Staging

Indexed keywords

FLUORODEOXYGLUCOSE;

ARTICLE; CANCER CLASSIFICATION; CANCER SCINTISCANNING; CANCER STAGING; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; LUNG NODULE; LUNG SCINTISCANNING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REIMBURSEMENT; UNITED STATES;

COIN LESION, PULMONARY; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED; UNITED STATES;

EID: 0032921197     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Stanley K, Stjernsward J. Lung cancer. In: Hansen HH, ed. Basic and Clinical Concepts of Lung Cancer. Norwell, MA: Kluwer; 1989:4-11.
2. Kurihara M, Aoki K, Hisamichi S. Cancer Mortality Statistics in the World: 1950-1985. Nagoya, Japan: University of Nagoya Press: 1989.
3. Magrath I, Litvak J. Cancer in developing countries: opportunity and challenge. J Natl Cancer Inst. 1993;85:862-873.
4. Boring CC, Squires TS, Tung T. Cancer statistics: 1992. CA Cancer J Clin. 1992;42:19-43.
5. Mack MJ, Hazelrigg SR, Landreneau RJ, Acuft TE. Thoracoscopy for the diagnosis of the indeterminate solitary pulmonary nodule. Ann Thorac Surg. 1993;56:825-832.
6. Smith TAD. FDG uptake, tumour characteristics, and response to therapy: a review. Nucl Med Commun. 1998;19:97-105.
7. Ginsberg RS, Vokes E, Raben A. Non-small cell cancer of the lung. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology. Philadelphia, PA: Lippincott-Raven; 1997:858-911.
8. Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsalainen U, Joensuu H. Influence of the blood glucose concentration on FDG uptake in cancer: a PET study. J Nucl Med. 1993;34:1-6.
9. Hoh CK, Hawkins RA, Glaspy JA, et al. Cancer detection with whole-body positron emission tomography using fluorodeoxyglucose. J Comput Assist Tomogr. 1993;17:582-589.
10. Spritzer CE, Norconk JJ Jr, Sostman HD, Coleman RE. Detection of deep venous thrombosis by magnetic resonance imaging. Chest. 1993;104:54-60.
11. Lowe VJ, Hoffman JM, DeLong DM, et al. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med. 1994;35:1771-1776.
12. 18F]fluorodeoxyglucose PET scanning. Radiology. 1993;188:487-490.
13. Lowe VJ, DeLong DM, Hoffman JM, Coleman RE. Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy. J Nucl Med. 1995;36:883-887.
14. Wahl RL, Quint LE, Greenough RL, et al. Staging of mediastinal non-small cell lung cancer with FDG PET, CT and fusion images: preliminary prospective evaluation. Radiology. 1994;191:371-377.
15. Lowe VJ, Coleman RE. Application of PET in oncology imaging. In: Sandler MP, Coleman RE, Wackers FJ Th, Patton JA, Gottschalk A, Hoffer PB, eds. Diagnostic Nuclear Medicine. 3rd ed. Baltimore, MD: Williams & Wilkins; 1995:1293-1308.
16. Mori K, Saitov Y, Tominaga K, et al. Small nodular lesions in the lung periphery: new approach to diagnosis with CT. Radiology. 1990;177:843-849.
17. Kuriyama K, Tateishi R, Doi O, et al. Prevalence of air bronchograms in small peripheral carcinomas of the lung on the thin-seetion CT: comparison with benign tumors. AJR. 1991;156:921-924.
18. Kubota K, Matsuzawa T, Fujiwara T, et al. Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J Nucl Med. 1990;31: 1927-1932.
19. Dehdashti F, Griffeth LK, McGuire AH, et al. FDG-PET evaluation of suspicious pulmonary and mediastinal masses [abstract]. J Nucl Med. 1992;33:961P.
20. 18F]FDG PET in the monitoring and management of response to lung cancer therapy [abstract]. Radiology. 1992;185:186P.
21. Strauss LG, Dimitrakopoulou AD, Haberkorn U, et al. PET follow-up studies to evaluate tumor perfusion and metabolism in patients with small cell carcinoma of the lung [abstract]. Radiology. 1992;185:139P.
22. Slosman DO, Spiliopoulos A, Couson F, et al. Satellite PET and lung cancer: a prospective study in surgical patients. Nucl Med Commun. 1993;14:955-961.
23. Knopp MV, Bischoff H, Ostertag H, et al. Clinical application of FDG-PET for staging of bronchogenic carcinoma [abstract]. J Nucl Med. 1993;34:21P.
24. Khonsary SA, Mandelkern MA, Brown CV, et al. PET-FDG scanning in pulmonary mass lesions [abstract]. Clin Nucl Med. 1993;18:922.
25. 18F]-FDG positron emission tomography with surgical pathology [abstract]. Eur J Nucl Med. 1994;21:62S.
26. Weber W, Romer W, Ziegler S, et al. Clinical value of F-18-FDG PET in solitary pulmonary nodules [abstract]. Eur J Nucl Med. 1995;22:775.
27. 18F-ftuoro-deoxyglucose in the assessment of solitary pulmonary nodules [abstract]. Eur J Nucl Med. 1995;22:775.
28. 18F]-fluorodeoxyglucose for preoperative staging of lung cancer: influence on patients' management [abstract]. Eur J Nucl Med. 1995;22:775.
29. Duhaylongsod FG, Lowe VJ, Patz EF, et al. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J Thorac Cardiovasc Surg. 1995;110:130-139.
30. Hubner KF, Buonocore E, Singh SK, et al. Characterization of chest masses by FDG positron emission tomography. Clin Nucl Med. 1995;20:293-298.
31. Dewan NA, Reeb SD, Gupta NC, et al. PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions: a comparative risk-benefit analysis. Chest. 1995;108:441-446.
32. Gupta NC, Maloof J, Gunel E. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med. 1996;37:943-948.
33. Lowe VJ, Duhaylongsod FG, Patz EF, et al. Pulmonary abnormalities and PET data analysis: a retrospective study. Radiology. 1997;202:435-439.
34. Lowe VJ, Fletcher JW, Gobar L, et al. Prospective investigation of PET in lung nodules. J Clin Oncol. 1998;16:1075-1084.
35. 18F]-FDG in oncology: a clinical update. Nucl Med Biol. 1996;23:717-735.
36. Duhaylongsod F, Lowe VJ, Patz EF, et al. Lung tumor growth correlates with glucose metabolism measured by FDG-PET. Ann Thorac Surg. 1995;60:1348-1352.
37. Coleman RE, Laymon CE, Turkington TG. FDG imaging of lung nodules: a phantom study comparing SPECT, camera-based PET and dedicated PET. Radiology. 1999;210:823-828.
38. 18F-fluorodeoxyglucose. AJR. 1998;170:1369-1373.
39. Higashi K, Ueda Y, Seki H, et al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med. 1998;39:1016-1020.
40. Ahuja V, Coleman RE, Herndon J, Patz EF Jr. Prognostic significance of FDG-PET imaging in patients with non-small cell lung cancer. Cancer. 1998;83: 918-924.
41. Webb WR, Gatsonis C, Zerhouni EA, et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. Radiology. 1991;178:705-713.
42. Grimmel S, Storck M, Henrich M, et al. Diagnostic value of 18-F-FDG-PET in patients with lung cancer and lymph node metastases [abstract]. Eur J Nucl Med. 1993;20:819.
43. Buchpiguel CA, Tse K, Alavi A, et al. Use of quantitative FDG-PET whole-body imaging in staging lung cancer: a comparison with CT [abstract]. Eur J Nucl Med. 1994;21:61S.
44. 18FDG in patients with bronchogenic carcinoma. Chest. 1994;108:1617-1621.
45. Sasaki M, Ichiya Y, Kuwabara Y, et al. The usefulness of FDG-PET for the detection of mediastinal lymph node metastases in patients with non-small-cell lung cancer: a comparative study with x-ray CT [abstract]. Eur J Nucl Med. 1994;21:189S.
46. 18F]fluorodeoxyglucose. Ann Thorac Surg. 1994;58:698-703.
47. Bury TH, Paulus P, Benoit TH, et al. Positron emission tomography versus computed tomography in the staging of mediastinal non-small-cell lung cancer [abstract]. Eur J Nucl Med. 1995;22:846.
48. Madar I, Hoh C, Figlin RA, et al. Cost-effective staging of non-small-cell lung carcinoma by whole-body PET FDG imaging [abstract]. J Nucl Med. 1995;36: 57P.
49. Chin R Jr, Ward R, Keyes JW Jr, et al. Mediastinal staging of non-small-cell lung cancer with positron emission tomography. Am 3 Respir Crit Care Med. 1995;152:2090-2096.
50. Valk PE, Pounds TR, Hopkins DM, et al. Staging lung cancer by PET imaging. Ann Thorac Surg. 1995;60:1573-1582.
51. Sasaki M, Ichiya Y, Kuwabara Y, et al. The usefulness of positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: a comparative study with x-ray computed tomography. Eur J Nucl Med. 1996;23:741-747.
52. Sazon DAD, Santiago SM, Soo GW, et al. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. Am J Respir Crit Care Med. 1996;153:412-421.
53. Engleman RM, McNamara WL. Bronchogenic carcinoma: a statistical review of two hundred twenty-four autopsies. J Thorac Surg. 1954;27:227-239.
54. Erasmus JJ, Patz EF, McAdams HP, et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using FDG-PET imaging. AJR Am J Roentgenol. 1997;168:1357-1360.
55. 18FDG in the staging of non-small cell lung cancer. Eur Respir J. 1997;10:2529-2534.
56. Hebert M, Lowe V, Hoffman J, et al. Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy. Am J Clin Oncol. 1996;19:416-421.
57. Ichija Y, Kuwabara Y, Sasaki M, et al. A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma. Ann Nucl Med. 1996;10:193-200.
58. Vansteenkiste J, Stoobants S, DeLyn P, et al. Prognostic significance of FDG-PET after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer (N2-NSCLC): analysis of 13 cases (abstract). Proc Am Soc Clin Oncol. 1998;16:75.
59. Patz EF Jr, Lowe VJ, Hoffman JM, Baine SS, Harris LK, Goodman PC. Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[-18]-2-deoxy-D-glucose. Radiology. 1994;191:379-382.
60. Inoue T, Kim EE, Komaki R, et al. Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med. 1995;36:788-793.
61. Gambhir SS, Hoh CG, Phelps ME, et al. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small cell lung carcinoma. J Nucl Med. 1996;37:1428-1436.
62. Scott WJ, Shepherd J, Gambhi SS. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis. Ann Thorac Surg. 1998;66:1876-1885.
63. Coleman RE, Tesar RD. Clinical PET: are we ready? J Nucl Med. 1997;38:8N-9N.
64. Coleman RE. Camera-based PET: the best is yet to come. J Nucl Med. 1997;38:1796-1797.
65. Delbeke D, Sandler MP, Al-Sugair A, et al. Comparison of dedicated and camera-based PET imaging of FDG in patients with focal pulmonary lesions [abstract]. J Nucl Med 1998;39:108P.